LaunchPad Medical has announced that the company has managed to win a 1.8 million USD grant from Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center.

The company has further added that this is the third grant it had received from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center as it had previously received a grant from the same company a while ago. The new grant will help the company to generate the data on Investigational Device Exemption (IDE) application and to conduct a pivotal animal study.

More than 40% of the patients who undergo dental implant have experienced the missing tooth at the start of the treatment. These types of patients must have to adopt several medication therapies to assist the healing process. These medial therapies help to increase the height and width of jawbone to replace the atrophied bone, so that a dental implant can be processed successfully.

Principal investigator of this grant and Professor, and Director, Postdoctoral Periodontics Program at the University of Pennsylvania School of Dental Medicine, Joseph P. Fioellini said, “Unlike most existing dental bone graft materials, this enhanced formulation of Tetranite resorbs and is replaced by bone on a timescale commensurate with existing graft materials but does not require ancillary containment devices like membranes or meshes or fixation aids like tacks and screws.”

“The clinical use of this material will reduce the time and complexity of ridge augmentation procedures and likely lead to more consistent results with regard to maintaining the original volume of grafts,” Joseph further added.

Co-Principal Investigator of the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center, William R. Wagner, PhD said, “This was a competitive process, and we are pleased with the progress that this research team has made. We look forward to the continued translation of this promising technology for clinical use in the third phase of our program.”